Acute erythroid leukemia: A reassessment using criteria refined in the 2008 WHO classification

Blood

Volumn 115, Issue 10, 2010, Pages 1985-1992

  Hasserjian, Robert P ^a   Zuo, Zhuang ^b   Garcia, Christine ^c   Tang, Guilin ^d   Kasyan, Armen ^b   Luthra, Rajyalakshmi ^b   Abruzzo, Lynne V ^b   Kantarjian, Hagop M ^e   Medeiros, L Jeffrey ^b   Wang, Sa A ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UMASS MEMORIAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CD135 ANTIGEN; LENALIDOMIDE; RAS PROTEIN; THALIDOMIDE;

ACUTE ERYTHROID LEUKEMIA; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLAST CELL; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; CYTOGENETICS; CYTOPENIA; DYSPLASIA; ERYTHROID CELL; ERYTHROID HYPERPLASIA; FEMALE; GENE MUTATION; HUMAN; HYPERPLASIA; KARYOTYPE; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; WORLD HEALTH ORGANIZATION;

EID: 77950403547     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-09-243964     Document Type: Article

References (26)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103(4):620-625.
2. Brunning RD, Matutes E, Flandrin G, et al. Acute myeloid leukaemia not otherwise categorised. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2001:91-105.
3. Arber A, Brunning RD, Orazi A, et al. Acute myeloid leukaemia with myelodysplasia-related changes. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008:124-126.
4. Zuo Z, Kasyan A, Chandra P, Medeiros J, Koeppen H. Acute erythroid leukemias: histologic, cytogenetic, and molecular characterization [abstract]. Lab Invest. 2009;89(S1):293A.
5. Park S, Picard F, Dreyfus F. Erythroleukemia: a need for a new definition. Leukemia. 2002;16(8): 1399-1401.
6. Lessard M, Struski S, Leymarie V, et al. Cytogenetic study of 75 erythroleukemias. Cancer Genet Cytogenet. 2005;163(2):113-122.
7. Selby DM, Valdez R, Schnitzer B, Ross CW, Finn WG. Diagnostic criteria for acute erythroleukemia. Blood. 2003;101(7):2895-2896.
8. Olopade OI, Thangavelu M, Larson RA, et al. Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood. 1992;80(11):2873-2882.
9. Fouillard L, Labopin M, Gorin NC, et al. Hematopoietic stem cell transplantation for de novo erythroleukemia: a study of the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2002;100(9):3135-3140.
10. Wang SA, Tang G, Fadare O, et al. Erythroidpredominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification. Mod Pathol. 2008;21(11):1394-1402.
11. Arber DA, Brunning RD, Orazi A, et al. Acute myeloid leukaemia, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer (IARC); 2008:130-139.
12. Santos FP, Faderl S, Garcia-Manero G, et al. Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia. 2009;23(12):2275-2280.
13. Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer (IARC); 2008:88-93.
14. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6): 2079-2088. (Pubitemid 27132124)
15. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial: The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92(7):2322-2333.
16. Lin P, Jones D, Medeiros LJ, Chen W, Vega-Vazquez F, Luthra R. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. Am J Clin Pathol. 2006;126(4):530-533. (Pubitemid 44498502)
17. Zuo Z, Chen SS, Chandra PK, et al. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol. 2009; 22(8):1023-1031.
18. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791-4797.
19. Wandt H, Schakel U, Kroschinsky F, et al. MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. Blood. 2008;111(4):1855-1861.
20. Weinberg OK, Seetharam M, Ren L, et al. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood. 2009;113(9):1906-1908.
21. Amin HM, Yang Y, Shen Y, et al. Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias. Leukemia. 2005;19(9):1567-1572. (Pubitemid 43090400)
22. Germing U, Strupp C, Kuendgen A, et al. Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals. Br J Haematol. 2006;132(2): 162-167. (Pubitemid 43381550)
23. Strupp C, Gattermann N, Giagounidis A, et al. Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals. Leuk Res. 2003;27(5): 397-404. (Pubitemid 36287201)
24. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-4395.
25. Hellström-Lindberg E, Kanter-Lewensohn L, Ost A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res. 1997;21(5):415-425. (Pubitemid 27308236)
26. Singh ZN, Huo D, Anastasi J, et al. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol. 2007;127(2):197-205. (Pubitemid 46797176)